Clinical trial • Phase III • Cardiology
nitroglycerin for Chronic kidney disease | Coronary artery disease
Phase III trial of nitroglycerin for Chronic kidney disease | Coronary artery disease. 36 participants.
Overview
- Trial Therapeutic Area
- Cardiology
- Trial Disease
- Chronic kidney disease | Coronary artery disease
- Trial Stage
- Phase III
- Drug Modality
- Small molecule | Small molecule
Key dates
- Initial CTIS Submission Date
- 08-10-2025
- First CTIS Authorization Date
- 22-01-2026
Trial design
Phase III trial in Germany, Bulgaria.
- Target Sample Size
- 36
Eligibility
Recruits 36 No vulnerable populations selected (isVulnerablePopulationSelected: false).
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected: false)
Recruitment
- Planned Sample Size
- 36
- Recruitment Window Months
- 7
Geography
- Total Number Of Sites
- 6
- Total Number Of Participants
- 36
Germany
- Earliest CTIS Part Ii Submission Date
- 08-01-2026
- Latest Decision Or Authorization Date
- 12-02-2026
- Processing Time Days
- 35
- Number Of Sites
- 4
- Number Of Participants
- 26
Sites
- Site Name
- Universitaetsklinikum Bonn AöR
- Department Name
- Phase I Einheit und Arzneimitteltherapiesicherheit
- Principal Investigator Name
- Martin Coenen
- Principal Investigator Email
- martin.coenen@ukbonn.de
- Contact Person Name
- Martin Coenen
- Contact Person Email
- martin.coenen@ukbonn.de
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Kardiologie, Angiologie und Intensivmedizin CVK
- Principal Investigator Name
- Frank Edelmann
- Principal Investigator Email
- frank.edelmann@dhzc-charite.de
- Contact Person Name
- Frank Edelmann
- Contact Person Email
- frank.edelmann@dhzc-charite.de
- Site Name
- SocraTec R&D Concepts in Drug Research and Development GmbH
- Department Name
- Clinical Pharmacology Unit
- Principal Investigator Name
- Victoria Reich
- Principal Investigator Email
- victoria.reich@socratec-pharma.de
- Contact Person Name
- Victoria Reich
- Contact Person Email
- victoria.reich@socratec-pharma.de
- Site Name
- Universitaetsklinikum Heidelberg AöR
- Department Name
- Klinische Pharmakologie und Pharmakoepidemologie
- Principal Investigator Name
- Antje Blank
- Principal Investigator Email
- antje.blank@med.uni-heidelberg.de
- Contact Person Name
- Antje Blank
- Contact Person Email
- antje.blank@med.uni-heidelberg.de
Bulgaria
- Earliest CTIS Part Ii Submission Date
- 02-02-2026
- Latest Decision Or Authorization Date
- 03-04-2026
- Processing Time Days
- 60
- Number Of Sites
- 2
- Number Of Participants
- 10
Sites
- Site Name
- Medical Center Comac Medical Ltd.
- Principal Investigator Name
- Tsvetan Kotsev
- Principal Investigator Email
- tsvetan.kotsev@comac-medical.com
- Contact Person Name
- Tsvetan Kotsev
- Contact Person Email
- tsvetan.kotsev@comac-medical.com
- Site Name
- Medical Center Comac Medical Ltd.
- Principal Investigator Name
- Tsvetan Kotsev
- Principal Investigator Email
- tsvetan.kotsev@comac-medical.com
- Contact Person Name
- Tsvetan Kotsev
- Contact Person Email
- tsvetan.kotsev@comac-medical.com
Sponsor
Primary sponsor
- Full Name
- Bayer AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- Nitroglycerin
- Active Substance
- nitroglycerin
- Modality
- Small molecule
- Investigational Product Name
- Nurandociguat
- Active Substance
- nurandociguat
- Modality
- Small molecule
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- METHYLPREDNISOLONE for Fulminant myocarditis
- PELACARSEN for Cardiovascular disease | Arteriosclerotic cardiovascular disease
- clopidogrel for Acute coronary syndrome | Cardiovascular diseases
- APIXABAN for Venous thromboembolism
- SOTAGLIFLOZIN for Obstructive hypertrophic cardiomyopathy | Non-obstructive hypertrophic cardiomyopathy